- Subject Team
Tong Yin
M.D., Associate director of the department, Chief Physician, Associated Professor of Medicine, Master’s Supervisor
Diagnosis and treatment of anemia, thrombocytopenia, hemorrhagic disorders, acute and chronic leukemia, lymphoma and multiple myeloma
Department of Hematology
Profile
Education&Training
09/2012-12/2013 Postdoctoral fellow
Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, The United States
03/2002-11/2003 M.D., Hematology
Kiel University, Kiel, Germany
09/1997-06/2000 Master’s Degree, Hematology
School of Medicine, Zhejiang University, Hangzhou, China
09/1992-06/1997 Bachelor’s degree, Clinical Medicine
Zhejiang Medical College, Hangzhou, China
09/2012-12/2013 Postdoctoral fellow
Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, The United States
03/2002-11/2003 M.D., Hematology
Kiel University, Kiel, Germany
09/1997-06/2000 Master’s Degree, Hematology
School of Medicine, Zhejiang University, Hangzhou, China
09/1992-06/1997 Bachelor’s degree, Clinical Medicine
Zhejiang Medical College, Hangzhou, China
Work Experiences:
01/2014--presentDepartment of Hematology, Shanghai General Hospital, Shanghai Jiao Tong University, Shanghai, China
09/2000-08/2012 Department of Hematology, Zhejiang Medical University Affiliated First Hospital, Hangzhou, Zhejiang, China
01/2014--presentDepartment of Hematology, Shanghai General Hospital, Shanghai Jiao Tong University, Shanghai, China
09/2000-08/2012 Department of Hematology, Zhejiang Medical University Affiliated First Hospital, Hangzhou, Zhejiang, China
Professional Memberships
Vice chairman, Youth Member, Shanghai Medical Association Hematology Branch Committee, 2016-present
Vice chairman, Youth Member, Shanghai Medical Association Hematology Branch Committee, 2016-present
Honors and Awards:
2011 Outstanding Staff, Zhejiang University
2000 Outstanding graduate, Zhejiang University
2011 Outstanding Staff, Zhejiang University
2000 Outstanding graduate, Zhejiang University
Selected Publications
1.Tong Y, Niu NF, Jenkins G, Batzler A, Li L, Kalali KR, Wang LW. Identification of genetic variants or genes that are associated with Homoharringtonine (HHT) response through a genome-wide association study in human lymphoblastoid cell lines (LCLs). Frontiers in Genetics, 2015. 5: 465（1-10）.
2.Tong Y, Zhu W, Huang X, You L, Han X, Yang C, Qian W. PI3K inhibitor LY294002 inhibits activation of the Akt/mTOR pathway induced by an oncolytic adenovirus expressing TRAIL and sensitizes multiple myeloma cells to the oncolytic virus. Oncol Rep. 2014; 31(4):1581-8.
3.Tong Y, You LS, Liu H, Li L, Meng HT, Qian WB. Potent antitumor activity of oncolytic adenovirus expressing Beclin-1 via induction of autophagic cell death in leukemia. Oncotarget. 2013; 4 (6):860-74.
4.Jin J, Wang JX, Chen FF, Wu DP, Hu J, Zhou JF, Hu JD, Wang JM, Li JY, Huang XJ, Ma J, Ji CY, Xu XP, Yu K, Ren HY, Zhou YH, Tong Y, Lou YJ, Ni WM, Tong HY, Wang HF, Mi YC, Du X, Chen BA, Shen Y, Chen Z, Chen SJ. Homoharringtonine-based induction regimens for patients with de-novo acute myeloid leukaemia: a multicentre, open-label, randomised, controlled phase 3 trial. Lancet Oncol. 2013 Jun;14(7):599-608
5.Lou Y, Qian W, Meng H, Mai W, Tong H, Tong Y, Huang J, Jin J. High efficacy of arsenic trioxide plus all-trans retinoic acid based induction and maintenance therapy in newly diagnosed acute promyelocytic leukemia. Leuk Res. 2013;37 (1):37-42.
6.Tong Y, Liu YY, You LS, Qian WB. Perifosine induces protective autophagy and upregulation of ATG5 in human chronic myelogenous leukemia cells in vitro. Acta Pharmacol Sin. 2012 ;33 (4):542-50.
7.Lou Y, Qian W, Meng H, Tong Y, Jin J. Frequent extramedullary recurrence of isolated myeloid sarcoma in the long-term follow-up. Ann Hematol 2012; 91(8):1317-9.
8.Yang C, Tong Y(co-first author), Ni W, Liu J, Xu W, Li L, Liu X, Meng H, Qian W. Inhibition of autophagy induced by overexpression of mda-7/interleukin-24 strongly augments the antileukemia activity in vitro and in vivo. Cancer Gene Ther. 2010; 17 (2):109-19.
9.Qian W, Liu J, Tong Y, Yan S, Yang C, Yang M, Liu X. Enhanced antitumor activity by a selective conditionally replicating adenovirus combining with MDA-7/interleukin-24 for B-lymphoblastic leukemia via induction of apoptosis. Leukemia.2008;22(2):361-9
10.Tong Y, Jin J, Marget M, Humpe A, Neppert J, Flesch BK. Variant FCGR3 genes:transcription and possible origins. Asian Pac J Allergy Immunol. 2008; 26 (4):223-8.
11.Tong Y, Qian J, Li Y, Meng H, Jin J. The high incidence of varicella herpes zoster with the use of bortezomib in 10 patients. Am J Hematol. 2007; 82 (5):403-4.
12.Tong Y, Jin J, Yan L, Neppert J, Marget M, Flesch BK. FCGR3B gene frequencies and FCGR3 variants in a Chinese population from Zhejiang Province. Ann Hematol. 2003; 82 (9):574-8.
1.Tong Y, Niu NF, Jenkins G, Batzler A, Li L, Kalali KR, Wang LW. Identification of genetic variants or genes that are associated with Homoharringtonine (HHT) response through a genome-wide association study in human lymphoblastoid cell lines (LCLs). Frontiers in Genetics, 2015. 5: 465（1-10）.
2.Tong Y, Zhu W, Huang X, You L, Han X, Yang C, Qian W. PI3K inhibitor LY294002 inhibits activation of the Akt/mTOR pathway induced by an oncolytic adenovirus expressing TRAIL and sensitizes multiple myeloma cells to the oncolytic virus. Oncol Rep. 2014; 31(4):1581-8.
3.Tong Y, You LS, Liu H, Li L, Meng HT, Qian WB. Potent antitumor activity of oncolytic adenovirus expressing Beclin-1 via induction of autophagic cell death in leukemia. Oncotarget. 2013; 4 (6):860-74.
4.Jin J, Wang JX, Chen FF, Wu DP, Hu J, Zhou JF, Hu JD, Wang JM, Li JY, Huang XJ, Ma J, Ji CY, Xu XP, Yu K, Ren HY, Zhou YH, Tong Y, Lou YJ, Ni WM, Tong HY, Wang HF, Mi YC, Du X, Chen BA, Shen Y, Chen Z, Chen SJ. Homoharringtonine-based induction regimens for patients with de-novo acute myeloid leukaemia: a multicentre, open-label, randomised, controlled phase 3 trial. Lancet Oncol. 2013 Jun;14(7):599-608
5.Lou Y, Qian W, Meng H, Mai W, Tong H, Tong Y, Huang J, Jin J. High efficacy of arsenic trioxide plus all-trans retinoic acid based induction and maintenance therapy in newly diagnosed acute promyelocytic leukemia. Leuk Res. 2013;37 (1):37-42.
6.Tong Y, Liu YY, You LS, Qian WB. Perifosine induces protective autophagy and upregulation of ATG5 in human chronic myelogenous leukemia cells in vitro. Acta Pharmacol Sin. 2012 ;33 (4):542-50.
7.Lou Y, Qian W, Meng H, Tong Y, Jin J. Frequent extramedullary recurrence of isolated myeloid sarcoma in the long-term follow-up. Ann Hematol 2012; 91(8):1317-9.
8.Yang C, Tong Y(co-first author), Ni W, Liu J, Xu W, Li L, Liu X, Meng H, Qian W. Inhibition of autophagy induced by overexpression of mda-7/interleukin-24 strongly augments the antileukemia activity in vitro and in vivo. Cancer Gene Ther. 2010; 17 (2):109-19.
9.Qian W, Liu J, Tong Y, Yan S, Yang C, Yang M, Liu X. Enhanced antitumor activity by a selective conditionally replicating adenovirus combining with MDA-7/interleukin-24 for B-lymphoblastic leukemia via induction of apoptosis. Leukemia.2008;22(2):361-9
10.Tong Y, Jin J, Marget M, Humpe A, Neppert J, Flesch BK. Variant FCGR3 genes:transcription and possible origins. Asian Pac J Allergy Immunol. 2008; 26 (4):223-8.
11.Tong Y, Qian J, Li Y, Meng H, Jin J. The high incidence of varicella herpes zoster with the use of bortezomib in 10 patients. Am J Hematol. 2007; 82 (5):403-4.
12.Tong Y, Jin J, Yan L, Neppert J, Marget M, Flesch BK. FCGR3B gene frequencies and FCGR3 variants in a Chinese population from Zhejiang Province. Ann Hematol. 2003; 82 (9):574-8.